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Abstract: Molecular genetic studies have identified several genes that may mediate 
susceptibility to attention defi cit hyperactivity disorder (ADHD). A consensus of the litera-
ture suggests that when there is a dysfunction in the “brain reward cascade,” especially in the 
dopamine system, causing a low or hypo-dopaminergic trait, the brain may require dopamine 
for individuals to avoid unpleasant feelings. This high-risk genetic trait leads to multiple drug-
seeking behaviors, because the drugs activate release of dopamine, which can diminish abnormal 
cravings. Moreover, this genetic trait is due in part to a form of a gene (DRD
2
 A1 allele) that 
prevents the expression of the normal laying down of dopamine receptors in brain reward sites. 
This gene, and others involved in neurophysiological processing of specifi c neurotransmitters, 
have been associated with defi cient functions and predispose individuals to have a high risk for 
addictive, impulsive, and compulsive behavioral propensities. It has been proposed that genetic 
variants of dopaminergic genes and other “reward genes” are important common determinants 
of reward defi ciency syndrome (RDS), which we hypothesize includes ADHD as a behavioral 
subtype. We further hypothesize that early diagnosis through genetic polymorphic identifi cation 
in combination with DNA-based customized nutraceutical administration to young children 
may attenuate behavioral symptoms associated with ADHD. Moreover, it is concluded that 
dopamine and serotonin releasers might be useful therapeutic adjuncts for the treatment of other 
RDS behavioral subtypes, including addictions.
Keywords: attention defi cit hyperactivity disorder (ADHD), genes, reward dependence, reward 
defi ciency syndrome, treatment, neuropsychological defi cits
Characteristics of attention defi cit hyperactivity 
disorder (ADHD)
Attention defi cit hyperactivity disorder (ADHD) is a complex disorder having multiple 
causes including genetics as impacted by one’s environment. The condition is usually 
diagnosed in childhood, when diffi culties arise during play and school, and it is marked 
by lack of concentration, short attention span, and physical restlessness (APA 1994; 
APA 2000). ADHD often is blamed on bad parenting, or a “bad” attitude. However, 
brain-imaging studies have shown that children with this disorder have an underlying 
neurological dysfunction, which likely accounts for their behavior (Zametkin et al 
1990; Lou et al 1998). In the simplest terms, the brains of these children have yet to 
come fully “on-line.” It is conjectured that while certain important brain pathways are 
working normally, cortical regions involved in attention, impulse control, and stimulus 
integration abilities, have yet to become fully active. ADHD is a widespread affl iction 
that we are just beginning to understand. People with ADHD suffer from overload 
(Miller and Blum 2008). That is, they have heightened awareness of incoming stimuli, 
particularly sight, sound, and touch. They are so bombarded by the normal stimuli 
in their environment that they cannot fi lter out the background noise, and they have 
trouble focusing or concentrating on a problem or a task. Because of their inability to 
focus, those with ADHD have trouble completing what they start. They have diffi culties 
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with making plans and even more diffi culty in carrying out 
plans in an orderly fashion.
People with ADHD tend to be disorganized. Children 
have messy rooms; adults have cluttered desks; daily activi-
ties tend to be chaotic. Attics and basements are likely to be 
fi lled with partly completed sewing projects, woodworking 
projects, repairs, and notebooks; desk drawers are likely to be 
cluttered with unfi nished letters, outlines, and project plans. 
Many people with the disorder are highly intelligent, but they 
tend to be underachievers because they cannot concentrate 
or sustain interest. As a result, family, friends, teachers, and 
coworkers become impatient and expect them to fail. People 
with ADHD also have trouble adapting to change. Their life 
is so full of tumult that even a minor additional change in 
their routine can be upsetting or can even create a crisis, eg, 
a parent goes away on a trip, a new teacher takes over a class, 
the family moves to a new city, or a pet dies.
ADHD affl icted people live under stress so severe they 
cannot tolerate frustration, and when they are frustrated, 
they are likely to become angry. The anger tends to come 
suddenly and explosively, accompanied by slamming doors, 
harsh words, tantrums, and leaving important meetings in a 
frenzy. Children get into fi ghts; adults lose jobs and alienate 
friends. Afterwards, they may be sorry, but the damage is 
done. With their high level of frustration, people with ADHD 
are impatient. They hate to wait in line, and delays of any 
kind can make them frantic. Whatever is going on – a trip, 
a movie, a class, a discussion – they want it to go quickly 
and be fi nished. Their impatience makes people with ADHD 
impulsive. As children, they leap into action without thinking 
of consequences. As adults, they drive too fast, use power 
tools carelessly, and plunge into activities without thinking of 
the danger. The result is they often hurt themselves or others. 
People with ADHD have trouble with their orientation to time 
and space. They may have trouble differentiating their right 
hand from their left; they may have diffi culty following a set 
of instructions, reading a map, or telling time. As babies or 
children they constantly are on the move, squirming, twist-
ing, and getting into everything. As adults, they are restless, 
easily bored, rebellious when asked to follow a routine, and 
always on the move. It is noteworthy that some of these 
characteristics are tied to comorbid Oppositional Defi ant 
Disorder (ODD) and conduct disorder (CD), separate from 
ADHD per se (Biederman et al 2007b).
The diagnosis of ADHD is based on criteria outlined 
by the Diagnostic and Statistical Manual of the American 
Psychiatric Association (DSM-IV; APA 1994). Table 1 lists 
these criteria. There have been a number of similar criteria 
set out in earlier versions of the DSM. While the names have 
changed somewhat, all have embraced the letters ADD in one 
form or another, representing the core of the disorder – atten-
tion defi cit disorder. The subtypes in the DMS-IV are ADHD-
I representing predominately the inattentive type, ADHD-H 
representing predominately the hyperactive-impulsive type, 
and ADHD-C, representing the combined type.
There has been increased interest in ADHD as a heritable 
neuropsychiatric condition linked to pathogenesis of brain 
dopamine (Shaw et al 2007; Swanson et al 2007; Volkow 
et al 2007). In the present paper, we discuss ADHD as an 
important putative complex subtype of a general condition 
or umbrella disorder known as reward defi ciency syndrome 
(RDS) (Blum et al 1996a). RDS refers to the breakdown 
of a cascade of neurotransmitters in the brain in which one 
reaction triggers another – the reward cascade (Blum and 
Kozlowski 1990b) – and resultant aberrant conduct (Blum 
et al 1996a). At the level of individual neurons, the reward 
cascade is catalyzed by a number of specifi c neurotransmit-
ters, each of which binds to certain types of receptors and 
serves a specifi c function. The binding of the neurotrans-
mitter to neuronal receptors triggers a reaction that is part 
of the cascade. Disruption of these intercellular cascades 
results in aberrant behavior of one form or another in RDS, 
including ADHD.
RDS has genetic and environmental infl uences, and it 
predisposes individuals to high risk for multiple addictive, 
impulsive, and compulsive behaviors. Depending on genes 
that control different parts of the reward neurotransmitter 
pathways, a person may display anything from mild anxiety, 
irritability, hyperactivity, or risk taking, to compulsive shop-
ping, gambling, sexual behaviors, drug addiction, alcoholism, 
smoking, and even eating disorders. Of all of these condi-
tions, one that is especially controversial and receives con-
siderable media coverage, is ADHD (APA 1994, 2000).
According to CHADD (Children and Adults with 
ADHD), 3.5 million school age children have ADHD 
(CHADD 2007). ADHD usually persists throughout a 
person’s lifetime. It is not limited to children. Approximately 
one-half to two–thirds of children with ADHD will con-
tinue to have signifi cant problems with ADHD symptoms 
and behaviors as adults, where it impacts their lives on the 
job, within the family, and in social relationships. ADHD 
is recognized as a disability under federal legislation (the 
Rehabilitation Act of 1973; the Americans with Disabilities 
Act; and the Individuals with Disabilities Education Act). 
Appropriate and reasonable accommodations are some-
times made at school for children with ADHD, and in the 
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workplace for adults with ADHD, which help the individual 
to work more effi ciently and productively. While teachers 
are not equipped to make a defi nitive diagnosis, they are 
a meaningful source of initiation of the process to attain a 
sound diagnosis (Biederman et al 2006). However, less than 
half of those individuals who have been targeted by teachers 
receive appropriate diagnosis and corrective intervention. 
Of those who are diagnosed, few are receiving appropriate 
multi-modal treatment apart from pharmacological manipu-
lation. Moreover, pediatricians report that approximately 
4% of their patients have ADHD. Boys are four times more 
likely to have this illness than girls.
Twin studies indicate that 75%–90% of ADHD is caused 
by genetic factors. If one person in a family is diagnosed 
with ADHD there is a 25%–35% probability that another 
family member also has ADHD, compared to a 4%–6% 
probability for someone in the general population. Between 
10% and 35% of children with ADHD have a fi rst degree 
relative with past or present ADHD. Approximately one-half 
of parents who had ADHD have a child with the disorder. 
There may be non-genetic factors as well, including prenatal 
exposure to nicotine by mothers who smoked, anoxia in the 
neonatal period of infancy, and childhood exposure to high 
quantities of lead.
Table 1 DSM-IV diagnostic criteria for attention-defi cit/hyperactivity disorder
A. Either (1) or (2) 
(1) six (or more) of the following symptoms of inattention have persisted for at least 6 months to a degree that is maladaptive and inconsistent with 
developmental level: 
  Inattention
  (a) often fails to give close attention to details or makes careless mistakes in schoolwork, work or other activities
  (b) often has diffi culty sustaining attention in tasks or play activities
  (c) often does not seem to listen when spoken to directly
  (d) often does not follow through on instructions and fails to fi nish schoolwork, chores, or duties in the workplace (not due to oppositional 
behavior or failure to understand instructions)
  (e) often has diffi culty organizing tasks and activities
  (f) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as schoolwork or homework)
  (g) often loses things necessary for tasks or activities (eg, toys, school assignments, pencils, books, or tools)
  (h) is often easily distracted by extraneous stimuli
  (i) is often forgetful in daily activities
(2) six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 months to a degree that is maladaptive and 
inconsistent with developmental level: 
  Hyperactivity
  (a) often fi dgets with hands or feet or squirms in seat
  (b) often leaves seat in classroom or in other situations in which remaining seated is expected
   (c) often runs about or climbs excessively in a situation in which it is inappropriate (in adolescents or adults, may be limited to subjective feelings 
of restlessness)
  (d) often has diffi culty playing or engaging in leisure activities quietly
  (e) is often “on the go” or often acts as if “driven by a motor”
  (f) often talks excessively
  Impulsivity
  (g) often blurts out answers before questions have been completed
  (h) often has diffi culty awaiting turn
  (i) often interrupts or intrudes on others (eg, butts into conversations or games)
B. Some hyperactivity-impulsive or inattentive symptoms that caused impairment were present before age 7 years
C. Some impairment from the symptoms is present in two or more settings (eg, at school [or work] and at home)
D. There must be clear evidence of clinically signifi cant impairment in social, academic, or occupational functioning 
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental Disorder, Schizophrenia, or other Psychotic Disorder and 
are not better accounted for by other mental disorder (eg, Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality Disorder).
Code based on type:
314.01 Attention-Defi cit/Hyperactivity Disorder, Combined Type: if both Criteria A1 and A2 are met for the past 6 months
314.00 Attention-Defi cit/Hyperactivity Disorder, Predominately Inattentive Type: if Criteria A1 is met but Criteria A2 is not met for the 
past 6 months
314.01 Attention-Defi cit/Hyperactivity Disorder, Predominately Hyperactive-Impulsive Type: if Criteria A2 is met but Criteria A1 is not 
met for the past 6 months
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Science of reward defi ciency 
syndrome
RDS results from a dysfunction in the “brain reward cas-
cade,” a complex interaction among brain neurotransmitters 
in reward centers of the brain, which directly links abnormal 
craving behavior with a defect in at least the DRD
2
 dopamine 
receptor gene (Blum and Kozlowski 1990a). Dopamine is a 
powerful brain neurotransmitter that controls feelings of well 
being (Blum and Kozlowski 1990b; Blum and Payne 1991; 
Blum et al 1996a). Dopamine interacts with other powerful 
brain chemicals and neurotransmitters (eg, serotonin and 
the opioids), which themselves are associated with control 
of moods. In individuals possessing an abnormality in the 
DRD
2
 dopamine receptor gene, the brain lacks suffi cient 
numbers of dopamine receptor sites to use the normal 
amount of dopamine in reward centers and thus reduces the 
amount of dopamine produced in this area. In individuals 
not possessing the variant in the dopamine receptor gene, 
but who have engaged in risky behaviors (such as cocaine 
abuse, extremely low caloric diet, high levels of stress over 
an extended period of time), the brain functions as though it 
had the DRD
2
 genetic variant (or other specifi c gene variants) 
(Faraone 2003). The overall effect is inadequate dopami-
nergic activity in brain reward centers. This defect drives 
individuals to engage in activities that will increase brain 
dopamine function. Consuming large quantities of alcohol or 
carbohydrates (carbohydrate bingeing) stimulates the brain’s 
production of, and utilization of, dopamine. So too does the 
intake of crack/cocaine and the abuse of nicotine. Also, it has 
been found that the genetic abnormality is associated with 
aggressive behavior, which also stimulates the brain’s use 
of dopamine (Blum et al 1996b, 2000).
RDS can be manifested in relatively mild or severe forms 
that follow as a consequence of an individual’s biochemical 
inability to derive reward from ordinary, everyday activities. 
At least one genetic aberration has been identifi ed that leads 
to an alteration in the reward pathways of the brain (Bowirrat 
and Oscar-Berman 2005). It is a variant form of the gene for 
the dopamine D
2
 receptor, called the A1 allele. This genetic 
variant also is associated with a spectrum of impulsive, 
compulsive, and addictive behaviors. The concept of the 
RDS unites those disorders and may explain how simple 
genetic anomalies give rise to complex aberrant behaviors. 
While this polymorphic gene may play a signifi cant role in 
ADHD predisposition, it must be tied to a certain subset of 
additional genes for the clinical expression of ADHD. This is 
called polygenic inheritance. Recent associations of certain 
alleles of both the dopamine D
4
 and dopamine D
2
 genes and 
novelty seeking behavior have confi rmed previous work 
suggesting polygenic inheritance (Comings et al 1996; Lee 
et al 2003).
Biology of reward
The reward system in the brain was discovered by accident in 
the 1950s by James Olds (Olds 1956). Olds had been studying 
brain mechanisms of attention using laboratory rats, when he 
mistakenly placed electrodes in a region of the limbic system. 
When the electrodes were attached so that the animals could 
self-stimulate this region by pressing a lever, rats would 
press the lever almost nonstop, as much as 5,000 times an 
hour. The animals would stimulate themselves to the exclu-
sion of everything else except sleep. They also would endure 
tremendous pain and deprivation for an opportunity to press the 
lever. Olds had clearly found an area in the limbic system that 
provided a powerful reward for these animals.
Later research on human subjects revealed that the 
electrical stimulation of the medial hypothalamus in the 
limbic system produced a feeling of quasi-orgasmic sexual 
arousal. If certain other areas of the brain were stimulated, 
an individual experienced a type of light-headedness that 
banished negative thoughts (Olds 1956; Blum et al 2000). 
These discoveries demonstrated that pleasure is a distinct 
neurological function that is linked to a complex reward 
and reinforcement system. During the past several decades, 
research has been able to better defi ne some of the brain 
regions and neurotransmitters involved in reward (Blum et al 
1996a, 2000). A neuronal circuit deep in the brain involving 
the limbic system, the nucleus accumbens, and the globus 
pallidus, appears to be critical in the expression of reward 
(Wise and Bozarth 1984). Although each substance of abuse 
or each addictive behavior may act on different parts of this 
circuit, the end result is the same: Dopamine appears to be 
the primary neurotransmitter released in brain reward sites 
(Koob and Bloom 1988).
Cascade theory of reward
Considerable attention has been devoted to the investigation 
of the neurochemical and neuroanatomical systems that 
underlie a variety of substance-seeking behaviors. In healthy 
people, neurotransmitters work together in a pattern of stimu-
lation or inhibition, the effects spreading downward, like a 
cascade, from stimulus input to complex patterns of response 
leading to feelings of well-being (cascade theory of reward; 
Stein and Belluzzi 1986; Blum and Kozlowski 1990b; 
Cloninger et al 1993). Although this neurotransmitter system 
is very complex and still not completely understood, the main 
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central reward areas in the human brain’s mesolimbic system 
are summarized below.
As can be seen in Figure 1, the following interactions 
take place in brain reward areas (Blum and Payne 1991; 
Stein and Belluzzi 1986): (1) Serotonin in the hypothalamus 
indirectly activates opiate receptors and causes a release 
of enkephalins in the ventral tegmental region A
10
. The 
enkephalins inhibit the fi ring of gamma-aminobutyric acid 
neurotransmitter (GABA), which originates in the substantia 
nigra A
9
 region. (2) GABA’s normal role, acting through 
GABA B receptors, is to inhibit and control the amount of 
dopamine released at the ventral tegmental regions for action 
at the nucleus accumbens. When dopamine is released in 
the nucleus accumbens, it activates dopamine D
2
 receptors. 
This release also is regulated by enkephalins acting through 
GABA. The supply of enkephalins is controlled by the amount 
of the neuropeptidases, which destroy them. (3) Dopamine 
also may be released into the amygdala. From the amygdala, 
dopamine exerts an effect on neurons within the hippocampus. 
(4) An alternate pathway involves norepinephrine in the 
locus ceruleus whose fi bers project into the hippocampus at 
a reward area centering around cluster cells, which have not 
been precisely identifi ed (designated as CAx). When GABA 
A receptors in the hippocampus are stimulated, they cause 
the release of norepinephrine.
It is to be noted that the putative glucose receptor in the 
hypothalamus is intricately involved and links the seroto-
nergic system with opioid peptides leading to the ultimate 
release of dopamine at the nucleus accumbens. In the brain 
reward cascade these interactions may be viewed as activities 
of subsystems of a larger system, taking place simultaneously 
or in sequence, merging in cascade fashion toward anxiety, 
anger, low self-esteem, or other unpleasant feelings, or 
toward craving of a substance that will reduce or eliminate 
the feelings (eg, alcohol, carbohydrates, alcohol, and drugs) 
(Blum and Kozlowski 1990b).
The notion of dopamine as the fi nal common pathway 
for a number of diverse drugs of abuse is supported by the 
fi ndings of Ortiz and associates (Ortiz et al 1995). They 
demonstrated that chronic administration of cocaine, mor-
phine, or alcohol resulted in several biochemical adaptations 
in the mesolimbic dopamine system. They suggested that 
these adaptations may underlie changes in the structural and 
functional properties of the neuronal pathway of this system 
related to substance abuse (Ollat et al 1990; also see Imperato 
and Di Chiara 1988).
Genetic anomalies, long-term continuing stress, or 
long-term abuse of substances can lead to a self-sustaining 
pattern of abnormal craving behavior in both animals and 
humans. Research on nonhuman animals has provided sup-
port for the cascade theory of reward and its genetic links. 
Thus, Li and colleagues (Russell et al 1988; Zhou et al 1991; 
McBride et al 1993, 1994; Li et al 2006) developed strains 
of alcohol-preferring (P) and non-preferring (NP) rat lines. 
They found that the P rats have the following neurochemi-
cal profi le: lower serotonin neurons in the hypothalamus; 
higher levels of enkephalin in the hypothalamus (due to a 
lower release); more GABA neurons in the nucleus accum-
bens; reduced dopamine supply at the nucleus accumbens; 
and reduced densities of dopamine D
2
 receptors in the 
mesolimbic areas.
In terms of genetics, especially as related to ADHD, a 
number of genes have been associated, and these candidate 
genes are all involved in the reward cascade. Comings et al 
(2000) described a subset of at least 42 gene variants, which 
associate with ADHD and contribute to the overall variance. 
Interestingly, these genes constitute the basis for the reward 
cascade including certain neurotransmitters but not limited to 
dopaminergic, serotonergic, enkephalinergic, catecholamin-
ergic, cholinergic, GABAergic, androgen receptors, as well 
as other putative transmitters, hormones, and their receptors 
and enzymes (both anabolic and catabolic).
In recent years, a number of reviews of the neurochemical 
basis of ADHD have emphasized the involvement of multiple 
neurotransmitters and emphasized that one single genetic 
defect cannot explain all of the data. Polygenic inheritance is 
uniquely capable of answering the question of how to account 
for both the range of comorbid disorders in ADHD and their 
interaction, but it fails to provide us with a true model of 
subsets of genes and their contribution to the variance of the 
disorder in question. One example of polygenic inheritance 
for ADHD was tested by Comings et al (2000). They found 
that three dopaminergic genes, DRD
2
, DAT
1
, and DBH, 
differentially associated with ADHD probands. Their results 
showed that these three genes were additive in their effect. 
Thus, individuals who had three out of three markers had 
the highest ADHD score; those with two of three had the 
next highest score; then one of three; and those with none 
of the three markers had the lowest ADHD score (Comings 
et al 1996). Moreover, this additive effect was also seen for 
a number of other related ADHD behaviors (ie, stuttering, 
obsessive compulsive disorder [OCD], tics, conduct disorder 
[CD]) and supports the polygenic hypothesis of ADHD. In 
other words, the different associated behaviors are due to 
similar sets of genes in that certain psychiatric disorders have 
a number of genes in common.
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Figure 1 Interactions in brain reward regions. (1) Serotonin in the hypothalamus indirectly activates opiate receptors and causes a release of enkephalins in the ventral 
tegmental region A10. The enkephalins inhibit the fi ring of GABA, which originates in the substantia nigra A9 region. (2) GABA’s normal role, acting through GABA B receptors, 
is to inhibit and control the amount of dopamine released at the ventral tegmental regions for action at the nucleus accumbens. When dopamine is released in the nucleus 
accumbens, it activates dopamine D2 receptors, a key reward site. This release is also regulated by enkephalins acting through GABA. The supply of enkephalins is controlled 
by the amount of the neuropeptidases that destroy them. (3) Dopamine also may be released into the amygdala. From the amygdala, dopamine stimulates the hippocampus 
and the CA and cluster cells stimulate dopamine D2 receptors. (4) An alternate pathway involves norepinephrine in the locus ceruleus whose fi bers project into the 
hippocampus at a reward area centering around cluster cells that have not been precisely identifi ed, but which have been designated as CAx. When GABA A receptors in 
the hippocampus are stimulated, they cause the release of norepinephrine.
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This suggests a four-part cascade sequence leading to a 
reduction of net dopamine release in a key reward area. Addi-
tional support for this idea came when investigators found 
that by administering substances that increase the serotonin 
supply at the synapse, or by stimulating dopamine D
2
 recep-
tors directly, they could reduce craving for alcohol (McBride 
et al 1994). Specifi cally, D
2
 receptor agonists reduced alcohol 
intake in high alcohol preferring rats, whereas D
2
 dopamine 
receptors antagonists increased alcohol drinking in these 
inbred animals (Dyr et al 1993).
Science of ADHD
Neuropsychogenetics of ADHD
In ADHD, the picture emerges of individuals suffering from 
overload, trying to adjust to a world that is too bright, too 
loud, too abrasive, and too rapidly changing for comfort. 
Early speculation about the causes of ADHD focused on such 
factors as marital disorder, poor parenting, brain damage, 
psychiatric illness, or alcoholism or drug abuse in the family. 
Associated behaviors included CD and anti-social personality. 
Later these behaviors were shown to be linked hereditarily to 
substance use disorder (SUD). Most recently, research has 
begun to show a signifi cant association between these behav-
ioral disorders, ADHD, and specifi c genetic anomalies.
What is the cause or basis of ADHD? It is an impulse dis-
order with genetic components that results from imbalances 
of neurotransmitters. Its effects can be eased by treatment 
and counseling. The biological basis for this disorder has 
been established by a number of investigators (Comings et al 
1991; Biederman et al 1992). In one study individuals with 
ADHD were found to have abnormal brain wave patterns 
(Lubar 1991). Their beta waves (brain waves associated with 
concentration) are low, and their theta waves (associated with 
relaxation) are high, suggesting a state of drowsiness and 
daydreaming. It is not surprising, therefore, that activities 
associated with beta waves, eg, watchful anticipation and 
problem solving, are diffi cult for individuals with ADHD to 
sustain. They like activities that permit them to stay in a theta 
state with a minimum of outside stimulation (Lubar 1991). It 
may be that people with ADHD are affl icted with a defective 
fi ltering system such that their brainstem reticular formation 
does not block out irrelevant stimuli. These people appear 
to be aware of every sound, every object, every touch, and 
they all merge in disorganized behaviors that are diffi cult to 
tolerate. Non-essential stimuli get the same attention as those 
essential to work or relating to other people. At a deeper level, 
ADHD is a problem of communication among brain cells, 
or neurons, possibly involving the neurotransmitters that 
carry inter-neural messages. These brain messengers may be 
either in short supply for certain behaviors such as cravings 
(probably due to inadequate serotonergic and or dopaminer-
gic function) or other attentional defi cits, or they may be the 
result of too much norepinephrine rather than too little. If the 
messengers that inhibit incoming stimuli are defi cient, too 
many signals get through and create confusion.
At a still deeper level, the problem lies in the genes that 
lay down the blueprint for manufacturing neurotransmitters. 
People with ADHD have at least one defective gene, the 
DRD
2
 gene that makes it diffi cult for neurons to respond to 
dopamine, the neurotransmitter that is involved in feelings of 
pleasure and the regulation of attention. Studies on genetic 
anomalies have implicated other dopaminergic genes such 
as the DRD
4
 receptor gene, the dopamine beta hydroxylase 
(DβH) gene, and the dopamine transporter genes as causative 
factors in ADHD (Cook et al 1995; Waldman et al 1996), as 
well as gene variants involved in multiple neurotransmitter 
pathways.
Support for the role of genetics in ADHD includes evi-
dence showing that it runs in families. For example, a number 
of studies have shown that fathers and/or mothers of ADHD 
children tend to have antisocial personality and alcohol-
ism. As early as 1971, James Morrison and Mark Stewart 
examined parents of 59 hyperactive children and 41 control 
children. In 21 of the families, at least 1 parent was alcoholic 
or had antisocial personality and other related behaviors. By 
contrast, only 4 of the control families were so affected. In a 
family study of parents and siblings of felons, there was an 
increased frequency of antisocial personality, alcoholism, 
and drug addiction in male relatives of hyperactive children 
(Cantwet al 1972).
Numerous studies indicate that 20%–30% of siblings 
of ADHD children also have ADHD. This is 2–7 times the 
frequency found in non-ADHD children. These siblings 
also were 5 times more likely to have major depression than 
control children (Welner et al 1977; August and Stewart 
1983). Other studies showed that 22% of brothers and 8% of 
sisters of hyperactive children were hyperactive themselves. 
Interestingly, however, when ADD is considered without 
hyperactivity, the number of brothers and sisters affected was 
the same (Cantwell 1976). In another study of ADHD chil-
dren it was found that if neither parent had the syndrome, 11% 
of the siblings had ADHD. If one parent had ADHD, 34% of 
the siblings had ADHD (Pauls and Leckman 1986).
The observed fact that ADHD parents have an ADHD 
child does not prove that the problem is genetic. The question 
can be asked, was the behavior learned? One answer to the 
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question is to look at siblings and half-siblings, both raised 
in the same environment. If ADHD is learned, the frequency 
should be the same for both. In actuality, half-siblings who 
have only half the genetic similarity show a signifi cantly 
decreased frequency of ADHD (Safer 1973). In a study of 
twins, Willerman (1973), found that if one identical twin had 
ADHD, the other also had ADHD. If non-identical twins had 
ADHD, only 17% of the other twins had ADHD. This fi nding 
was confi rmed in other independent studies.
Another approach is to look at the parents of ADHD 
children given up for adoption. If ADHD is a genetic disor-
der, the parents of children with the problem should show 
a higher frequency of ADHD, antisocial personality, or 
alcoholism than the adopting parents. In a study of ADHD 
children of ADHD parents who gave up their children at birth 
for adoption, it was found that the rate of antisocial person-
ality, alcoholism, and ADHD was higher in the biological 
parents than in the adopting parents. In a study by Comings 
et al (1991), the investigators found that the A
1
 allele of the 
dopamine D
2
 receptor gene was present in 49% of a sample 
of ADHD children compared to only 27% of controls. This 
was confi rmed by Blum and associates (1993).
To some extent, people with ADHD can learn to cope. 
They can avoid situations that generate stress; avoid crowds 
and noisy environments; give themselves plenty of time 
and avoid tight deadlines; and avoid rapid changes in their 
environment. The most destructive coping strategy is self-
medication with alcohol or drugs. Such substances give the 
illusion that they are making life easier and more pleasant, for 
the symptoms seem to disappear. But the addiction quickly 
takes over, and life becomes a nightmare (Faraone et al 1991). 
Then, when they withdraw from alcohol or drugs, the ADHD 
problems return in full force.
The inherent tragedy here is that the ADHD person may 
be genetically at risk of developing an addiction. Possibly 
the same neurochemical imbalance in their brain that 
produces ADHD also produces a predisposition to addiction, 
Tourette syndrome, ODD, CD, and as well as other related 
behaviors (Comings et al 1991; Blum et al 1996b; Miller 
and Blum 2008).
Behavioral and electrophysiological 
diagnostic tools
In clinical settings, a number of rating scales have been 
utilized with mixed results for the diagnosis of ADHD. 
One set of commonly employed tools involves the Con-
ners’ Rating Scales (Conners 2006), an instrument that uses 
observer ratings and self-reports to help evaluate problem 
behaviors in children and adolescents. Another alternative 
utilized in a clinical setting to assist in properly diagnosing 
ADHD is a continuous performance test called T.O.V.A. 
(Test of Variables of Attention) (TOVA 2006). The latest 
version of this test is computerized, and it is designed to 
identify a minimum of four types of attention failures. One 
type is marked by omission abnormalities when the patient’s 
attention failure is measured by missing information. The 
problem with relying on this parameter is that omission 
errors have been associated with a wide spectrum, includ-
ing schizophrenia and petit mal seizure disorder, in which 
the attention failure is marked by neurological absences. 
The second type is marked by commission abnormalities 
associated with impulsive behaviors, and it frequently is 
co-morbid with a cluster of anxiety disorders (eg, obsessive 
compulsive behaviors, panic, and oppositional defi ance). 
The third type is marked by abnormalities in reaction time. 
It is believed that this type is not specifi c for ADHD and is 
associated with slowing of response times as seen in classic 
psychomotor retardation, dysthymia, and major depression. 
The fourth type is response variability (either fast or slow). 
Of all the above, this is more closely related to ADHD and is 
also common in adults that have obesity, alcoholism, and/or 
craving disorders. It is this fourth type that is most likely 
linked to dopaminergic defi ciency. However, it is important 
to note that results of T.O.V.A. tests have been associated 
with a number of false negative diagnoses.
To test the relationship between response variability and 
dopaminergic defi ciency, we embarked on a study that exam-
ined associations between dopamine D
2
 receptor variants and 
T.O.V.A. scores (including response variability), as well as 
a measure of brain electrical activity, the P300 event related 
brain potential (Noble et al 1994). We studied 100 patients 
entering the PATH Medical Clinic, New York City, for a 
variety of medical complaints including neuropsychiatric, 
cardiovascular, and oncological problems. Each patient was 
given the T.O.V.A. and brain electrical activity mapping. 
When all the T.O.V.A. scores were summed (1 standard 
deviation above the norm) a signifi cant linear trend was 
observed, whereby increasing abnormal T.O.V.A. scores 
were associated with a percentage of patients having an 
abnormal prolonged P300 latency (normal being 300 plus 
age). Moreover, we found signifi cant differences between 
the various scores (inattention, impulsivity, response time, 
and variability) and abnormal P300 latency (Braverman et al 
2006). In contrast, only variability response was signifi cant 
for P300 amplitude. This site-specifi c association may be 
attributable to dopaminergic variants. It is well known that 
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the DRD
2
 gene A1 allele is associated with abnormalities 
in both the P300 latency and amplitude in well-screened 
alcoholics (Noble et al 1994). Thus, we must caution the 
clinician in terms of utilizing only one diagnostic tool to 
diagnose ADHD. We alternatively suggest that a number of 
tests including both Conners and T.O.V.A., as well as gene 
testing, be employed together.
ADHD is a common disorder
Estimates of the frequency of the various types of ADHD, 
based on population surveys, have shown variable results. 
A fairly common range is illustrated in Table 2. The advan-
tage of population based samples, in contrast to clinic based 
samples, is that individuals in the community who have 
not sought medical attention are included in the sample. In 
most locations, far fewer than 16%, and usually less than 
4%, of the children in a given population receive treatment 
for a form of ADHD. This is contrary to the notion that the 
ADHD is overdiagnosed and overtreated. In fact, the majority 
of symptomatic children are not treated. Other associated 
disorders include CD and ODD.
While many of these children can be handled by appro-
priate teaching methods and do not require treatment, 
these fi gures suggest that ADHD-I at least, is probably 
under diagnosed and under treated. While the sex ratio for 
ADD-H and ADHD-C is 4:1, the sex ratio for ADD-I is closer 
to 1:1. This is a refl ection of the fact that ADHD in girls 
tends to present as the inattentive type while boys are more 
likely to present as the hyperactive-impulsive or combined 
type. Symptoms of hyperactivity and impulsivity in school 
are obvious and disruptive, whereas symptoms of inattention 
are more subtle and non-disruptive; consequently, boys tend 
to be diagnosed and treated more than girls.
ADHD is a spectrum disorder
It has been known for many years that if an individual inherits 
enough genes to develop any given behavioral disorder, the 
risk of developing a second behavioral disorder is two to four 
times greater than for the general population. This is likely 
due to the fact that different behavioral disorders share some 
gene variants in common. Thus, the more a person exceeds 
the required threshold number of gene variants, the greater 
the likelihood of developing more than one behavioral prob-
lem, thus the term spectrum disorders. Some of the most 
common coexisting or comorbid spectrum disorders seen 
in individuals with ADHD are ODD, CD, major depressive 
disorder, anxiety disorders, OCD, bipolar disorder, learning 
disorders, and substance abuse disorder including alcoholism 
and drug addiction.
ADHD has lifelong effects
Having pointed out that much of the poor outcome in ADHD 
children is due to the comorbid presence of CD, we would 
still like to present the studies of a 1985 report of Howell 
and coworkers (Howell et al 1985). While this longitudinal 
study did not distinguish between ADHD and ADHD plus 
CD, it did something no other study has done. The study 
compared the outcome of three groups of children instead 
of just ADHD children and controls. Children in the early 
grade school years were evaluated on a continuum of ADHD 
symptoms and divided into three groups, those scoring in the 
highest 10% (ADHD group) those in the lowest 10% (low 
ADHD group) and the rest (“normal” group). They were 
then re-evaluated after they graduated from high school. The 
remarkable fi nding was that in virtually every aspect of their 
life the low ADHD group performed best, the normal indi-
viduals were intermediate and the ADHD group performed 
worst. This should not be taken to suggest that children with 
ADHD always underachieve. Again, we wish to emphasize 
there are many examples in which the restless, workaholic, 
always-have-to-be-doing-something, I-need-to-be-my-
own-boss, characteristics of ADHD subjects result in very 
successful lives. Thus, in the right combination, some of the 
symptoms we have been discussing in a negative light can 
be used to great advantage (Comings et al 2005).
Genes and ADHD
It has been proposed that ADHD is a polygenic disorder 
due to the additive effect of genes affecting dopamine, 
norepinephrine, serotonin, GABA, and other neurotransmit-
ters (eg, see Comings et al 2000). Some of the specifi c loci 
involved are dopamine genes DRD
1
, DRD
2
, DRD
4
, DRD
5
, 
dopamine–beta-hydroxylase, and the dopamine transporter; 
norepinephrine and epinephrine genes ADRA2A, ADRA2C, 
PNMT, norepinephrine transporter, MAOA, catechol-O-
methyltransferase (COMT); serotonin genes TDO2, HTR1A, 
HTR1DA, serotonin transporter; GABA genes GABRB3; 
androgen receptor and other genes. This model is consistent 
Table 2 Prevalence of various types of ADHD in the general 
population
Hyperactive/Impulsive 2.6
Inattentive 8.8
Combined 4.7
Total 16.1
 M/F ratio 4:1
After Wolraich et al (1998).
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with present knowledge about ADHD including the following 
(Comings et al 2000): (a) the increased frequency of ADHD 
in the relatives of ADHD probands, (b) the presence of a 
wide spectrum of comorbid behaviors (depression, anxiety, 
learning, CD, ODD, and substance abuse disorders) in ADHD 
probands and their relatives on both parental sides, (c) the 
close relationship to Tourette syndrome, (d) the failure to 
fi nd the genes for Tourette syndrome using linkage analysis, 
(e) the brain imaging studies showing hypometabolism of 
the frontal lobes, (f) the relationship between dopamine D
2
 
receptor density and regional blood fl ow, (g) the correla-
tion between cerebral spinal fl uid homovanilic acid levels 
and DRD
2
 genotypes, (h) the correlation between tics and 
dopamine D
2
 receptor density in Tourette syndrome, (i) the 
motor hyperactivity of dopamine transporter and dopamine 
D
3
 receptor gene knockout mice, (j) the Le Moal and Simon 
(1991) and Shaywitz et al (1976) dopamine defi ciency animal 
models of ADHD, (k) the norepinephrine models of ADHD, 
(l) the failure to explain ADHD on the basis of any single 
neurotransmitter defect, (m) the response of ADHD to dopa-
mine and alpha-adrenergic agonists, (n) the small percentage 
of the variance of specifi c behaviors accounted for by each 
gene, and numerous other aspects of ADHD.
In one recent study (Brookes et al 2006), 1,038 single-
nucleotide polymorphisms (SNPs) spanning 51 candidate 
genes involved in the regulation of neurotransmitter path-
ways, particularly dopamine, norepinephrine, and serotonin 
pathways, in addition to circadian rhythm genes, revealed 
interesting results. The analyses involved within-family tests 
of association in a sample of 776 DSM-IV ADHD combined-
type cases ascertained for an international multi-centre 
ADHD gene project. The researchers found nominal signifi -
cance with one or more SNPs in 18 genes, including the two 
most replicated fi ndings in the literature: DRD
4
 and DAT
1
. 
Gene-wide tests, adjusted for the number of single nucleo-
tide polymorphisms (SNPs) analyzed in each gene, identi-
fi ed associations with the following: serotonergic (TPH2), 
adrenergic (ARRB2, ADRB2), dopaminergic (DAT
1
), neu-
rotransmitter metabolizing (MAO), pituitary development 
(HES1), enkephalinergic (PNMT), and synapase regulator 
(synaptophysin II [syp II]) gene polymorphisms.
Molecular genetics and ADHD
ADHD is not caused by poor parenting, family problems, poor 
teachers or schools, too much TV, food allergies or excess 
sugar. Instead, it is caused by biological and genetic factors 
that infl uence neurotransmitter activity in certain parts of the 
brain (Wallis et al 2008). Studies at the National Institute of 
Mental Health using positron emission tomography (PET) 
scans to observe the brain at work have shown a link between 
a person’s ability to pay continued attention and the level of 
activity in the brain. In people with ADHD, the brain areas 
that control attention used less glucose, indicating that they 
were less active. It appears from this research that a lower 
level of activity in some parts of the brain may cause inatten-
tion and other ADHD symptoms (Ernst et al 1988).
A dopamine model
Defects in dopamine metabolism have long been implicated in 
the etiology of ADHD. There are many reasons for this (Com-
ings et al 1991; Kirley et al 2003): (1) LeMoal and Simon 
(1991) showed that lesions of the dopaminergic neurons of 
the ventral tegmental area resulted in hyperactivity, hyper-
responsivity, poor response to stress, and a spectrum of other 
disorders. (2) Shaywitz and colleagues (1976) showed that 
chemical destruction of frontal lobe dopaminergic neurons 
shortly after birth produced an animal model of ADHD that 
responded to stimulants. (3) Catecholamines in the cerebral 
spinal fl uid (CSF) of children with Tourette syndrome showed 
signifi cantly lower levels of homovanillic acid (Leckman et al 
1995). Some have also reported low CSF homovanillic acid in 
children with ADHD, while more recent studies have shown 
a positive correlation between CSF homovanillic acid and 
scores of hyperactivity and conduct disorder ADHD (Gerra 
et al 2007). (4) Brain imaging studies showed defects in the 
dopamine-rich striatum in ADHD (Krause et al 2003). (5) Fur-
thermore, brain imaging studies indicate hypofunctionality of 
the frontal lobes in ADHD and Tourette syndrome. (6) Other 
studies have shown hyperactivity in knockout mice missing 
the dopamine transporter or DRD
3
 genes. (7) Further evidence 
demonstrated the effectiveness of dopaminergic agonists in 
the treatment of ADHD (la Fougere et al 2006). The following 
are some of the specifi c dopaminergic genes that have been 
implicated in the etiology of ADHD (see Figure 1).
Dopamine D2 receptor gene (DRD2)
The fi rst molecular genetic studies of ADHD were reported 
in 1991 by Comings et al following the discovery by Blum 
and associates linking DRD
2
 A1 allele to severe alcoholism 
(Blum et al 1990). They examined the prevalence of the Taq 
A1 allele of the DRD
2
 gene in impulsive, compulsive, addic-
tive behaviors. These results suggested that genetic variants 
at the DRD
2
 locus played a role in a range of impulsive, 
compulsive, addictive disorders, including ADHD. The 
prevalence of the D
2
A1 allele in these disorders ranged from 
42.3 to 54.5%. While it was clear that the DRD
2
 was not a 
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major gene causing these conditions, since it was usually not 
even present in half of the cases, it was also clear that the 
prevalence of the D
2
A1 allele was approximately two-fold 
higher than in controls. An indication of the importance of 
the dopamine D
2
 receptor in Tourette syndrome comes from 
SPECT (single photon emission computed tomography) 
studies of monozygotic twins discordant for tic severity. 
For example, differences in D
2
 receptor density in the head 
of the caudate nucleus predicted differences in phenotypic 
severity with the almost unheard of correlation coeffi cient 
of r = 0.99, p  0.001, suggesting that striatal dopamine D
2
 
receptor density accounted for 98% of the variance of tic 
severity (Wolf et al 1996).
In a subsequent study of individuals who smoked at 
least one pack of cigarettes per day and were unable to quit 
on their own, it was found that 48% carried the Taq I D
2
A1 
allele (Comings et al 1996a) and had trouble sleeping 
(Vandenbergh et al 2007). The prevalence Taq I D
2
A1 allele 
was even higher in a large group of pathological gamblers 
(Comings et al 1996b). It was also verifi ed in post-traumatic 
stress disorder (Lawford et al 2006). The initial interpre-
tation was that the DRD
2
 gene modifi ed the effect of an 
unidentifi ed major gene for Tourette syndrome and ADHD. 
The important feature is that the DRD
2
 gene accounted for 
less than 5% of the variance of a number of quantitative traits 
relating to ADHD and other behaviors. As the number of 
genes showing a similar modest effect were identifi ed (see 
below), and as the failure to fi nd any gene causing a major 
effect continued, we and others began to favor the polygenic 
mode of inheritance for ADHD, Tourette syndrome, and 
other psychiatric disorders (Noble 2003). Moreover, recent 
work indicates that other RDS related behaviors including 
adolescent excessive internet video gaming are signifi cantly 
associated with the DRD
2
 A1 allele (Han et al 2007). Inter-
estingly, in both Borderline Personality Disorder as well 
as healthy individuals, the presence of the DRD
2
 A1 allele 
correlated with the commission of more time violations 
on a test sensitive to the integrity of the frontal lobes, and 
especially in the healthy subjects, with longer execution 
times. This work suggests that the DRD
2
 gene could exert 
an effect on executive functioning controlled by frontal 
brain systems.
Dopamine D2 receptors, regional blood 
fl ow, and response to methylphenidate
In reviews of published articles that examined striatal dopa-
mine transporter (DAT) density in ADHD patients, Krause 
et al (2003; 2006) cited numerous neuroimaging fi ndings of 
elevation in that region. Additionally, Krause et al (2005) 
investigated whether availability of striatal DAT may have 
an infl uence on the response of adult ADHD patients to 
methylphenidate, as measured with SPECT scans. They found 
that ADHD individuals with low DAT availability failed to 
respond to methylphenenidate therapy. Also using SPECT 
technology, Volkow and colleagues (1995, 1997) examined 
the relationship between the effects of methylphenidate on 
regional blood fl ow and the density of dopamine D
2
 receptors 
in various regions of the brain. In some subjects, methylpheni-
date increased regional blood fl ow while in others it decreased 
blood fl ow. The changes in the frontal, temporal and cerebellar 
metabolism were related to the density of D
2
 receptors – the 
higher the density the greater the increases in blood fl ow. 
Methylphenidate decreased the relative metabolic activity of 
the basal ganglia. These results are consistent, indicating that 
genetic defects in dopamine metabolism, resulting in a hypo-
dopaminergic state in the limbic system and frontal lobes, 
result in a compensatory increase in dopaminergic activity 
in the basal ganglia, and that methylphenidate reverses these 
through a combination of enhancing brain dopamine activity 
by inhibition of the dopamine transporter, with a secondary 
decrease in dopaminergic activity in the basal ganglia and a 
decrease in basal ganglia blood fl ow. These studies are also 
consistent with the results of Castellanos and colleagues 
(1998) showing a positive correlation between the response 
to methylphenidate and CSF levels of homovanillic acid, a 
metabolite of dopamine whose levels in the CSF are related 
to D
2
 receptor density.
One of the intriguing aspects of the Volkow et al (1995) 
study was the fi nding that methylphenidate consistently 
increased cerebellar metabolism, despite the paucity of D
2
 
receptors in this structure. This is consistent with the increas-
ing evidence that the cerebellum plays an important role in 
attention, learning, and memory.
In support of the above studies, Noble et al (1997) also 
found an association between the Taq I D
2
A1 genotype 
and regional blood fl ow. Using PET and 18F-deoxyglucose, 
they observed that A1 carriers showed a significantly 
lower relative glucose metabolism in the putamen, nucleus 
accumbens, frontal and temporal gyri and medial prefrontal, 
occipito-temporal and orbital cortices than those with the A22 
genotype. Noble and Blum and associates had previously 
shown that Taq I D
2
A1 carriers had a signifi cantly decreased 
dopamine D
2
 receptor in the basal ganglia. In a different PET 
study, Farde et al (1997) observed a signifi cant decrease in 
dopamine D
2
 receptor density in individuals with detachment, 
social isolation, and lack of intimate friendships.
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Heterosis at the DRD2 gene
Within the past decade, Comings et al have examined the role 
of the DRD
2
 gene in a range of behaviors, and have noticed 
a persistent tendency for quantitative behavioral scores to be 
highest in 12 heterozygotes, lowest in 11 homozygotes, and 
intermediate in 22 homozygotes. Most often the relationship 
is 122211 or 12 11 = 22. The presence of a greater 
effect in heterozygotes than either homozygote is termed het-
erosis. Strong support for heterosis at the DRD
2
 gene comes 
from research by Jönsson et al (1996). They compared the 
CSF levels of the dopamine breakdown product homovanillic 
acid to the DRD
2
 genotype using the Taq I D
2
A1 polymor-
phism. There was a remarkable similarity to the profi le for 
the inattention score in the Tourette syndrome subjects, with 
12 heterozygotes showing the highest inattention score, and 
the Jönsson et al (1996) subjects who were 12 heterozygotes 
had the lowest levels of CSF homovanillic acid. The highest 
levels of homovanillic acid were seen in the 11 homozygotes, 
with the levels in 22 homozygotes being intermediate. This 
suggests that subjects with the lowest levels of CSF homova-
nillic acid had the most symptoms of ADHD. While this is 
consistent with some studies showing a signifi cantly lower 
level of CSF homovanillic acid in children with ADHD 
and Tourette syndrome, it seems to confl ict with the studies 
of Castellanos et al (1998) showing a positive correlation 
among some aspects of symptom severity and response to 
methylphenidate, and CSF homovanillic acid levels. How-
ever, these studies only examined children with ADHD and 
did not include controls. While it is yet to be studied, those 
individuals carrying the Taq I D
2
A1 allele may not be those 
who respond best to methylphenidate.
Recent PET and SPECT studies of the relationship 
between the Taq I genotypes of the DRD
2
 gene and number 
of dopamine D
2
 receptors in the striatum, support the effect 
of molecular heterosis producing the lowest level of D
2
 
receptors in 12 heterozygotes, the highest levels in 11 homo-
zygotes and high levels in 22 homozygotes. These combined 
results provide the fi rst illustration of a direct connection 
between a genotype, a neurotransmitter level (dopamine), 
and ADHD symptoms. While the studies of homovanillic 
acid levels in ADHD have been variable, these results sug-
gest that some ADHD is associated with low CSF levels of 
homovanillic acid and this in turn is related to heterozygosity 
for the DRD
2
 Taq I alleles. In contrast, Noble et al (1994) 
found that the lowest level of D
2
 density was found in the 
11 homozygote.
In an attempt to further our understanding of the role of 
genes in ADHD as a subtype behavior of RDS, we embarked 
on a research study involving generational family-based 
subjects genotyped for three dopaminergic genes.
Dopamine transporter gene
The dopamine transporter is responsible for moving dopa-
mine across the presynaptic membrane back into the nerve 
cell from which it was released. In a recent review of the lit-
erature (Comings et al 2005), the DAT
1
 gene was considered 
an important candidate gene for ADHD, because it is a major 
dopaminergic gene, and it is the site of action of methylphe-
nidate and dexedrine, widely used in the treatment of ADHD. 
These stimulant medications inhibit the transport process, 
resulting in an increase in synaptic dopamine. Cook et al 
(1995) reported a signifi cant positive association between the 
10 allele of the DAT
1
 gene and 49 cases of ADHD using the 
haplotype relative risk procedure. When eight cases of undif-
ferentiated ADD were added, the results were unchanged. 
Using the family based haplotype relative risk procedure, Gill 
et al (1997) also found a signifi cant preferential transmission 
of the 10 allele in 40 parent-child sets.
Comings (2001) also observed a signifi cant association 
between the 10 allele and ADHD and a range of other behav-
ioral variables in Tourette syndrome probands. For example, 
in a group of 352 Tourette syndrome probands and control 
subjects, the mean cumulative ADHD score based on counts 
of DSM-III ADHD criteria, was 25.44 for those that were 
10/10 homozygotes versus 20.42 for those that were not 10/10 
homozygotes. Consistent with these results, Malison et al 
(1995), using SPECT imaging, reported a signifi cant increase 
in the level of dopamine transporter protein in the striatum 
of Tourette syndrome subjects compared to controls.
Knockout mice missing the DAT
1
 genes are very 
hyperactive. While these mice show increased motor 
activity in open fi eld studies, they were dramatically more 
hyperactive in smaller spaces. This suggests that the stress 
of being confi ned contributes to the hyperactivity. This is 
analogous to the contribution of the DRD
2
 gene to both 
hyperactivity and poor response to stress in humans. Studies 
of the DAT knockout mice showed a fi ve-fold increase in 
brain dopamine levels, down-regulation of D
2
 receptors, 
uncoupling of D
2
 receptor function, and a 57% decrease in 
body size. While the presence of hyperactivity in the absence 
of DAT
1
 genes may seem to confl ict with the above results, 
suggesting hyperactivity in the presence of increased activity 
of the human DAT
1
 gene, the presence of compensatory and 
plastic changes in other dopaminergic systems occurring 
when major defects of the dopamine transporter are 
present from conception, may account for the differences. 
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Alternatively, because of complex inhibitory and stimulatory 
loops, both increases and decreases (too much or too little) 
in the amount of receptor or transport protein may result in 
similar symptoms. In contrast to the above results, LaHoste 
et al (1996) did not fi nd a signifi cant increase in the frequency 
of the DAT
1
 10 allele in their group of ADHD subjects. They 
showed, instead, an increase in the prevalence of the 7 allele 
of the DRD
4
 gene.
Waldman et al (1998) have also examined the role of 
the DAT
1
 gene in ADHD. In their fi rst report, they used 
the transmission disequilibrium technique (a family-based 
association test to examine the linkage between a genetic 
marker and a trait) to determine the role of the DAT
1
 gene 
in ADHD, ODD and CD in 123 families. They found a 
signifi cant association between the DAT
1
 10 allele and 
ODD, CD, and hyperactivity-impulsivity. After controlling 
for the level of hyperactivity-impulsivity symptoms, the 
association with ODD and CD was no longer signifi cant, 
suggesting that the relationship between childhood ODD 
and CD was mediated through its effect on hyperactivity 
and impulsivity. In a subsequent report, they examined 
74 ADHD probands, 79 siblings, and a control sample of 
49 twins. The mean scores for hyperactivity/impulsivity, 
inattentiveness, ODD, CD, and depression and dysthymia 
were progressively lower across these three groups. The 
inclusion of parents allowed family based association 
studies. It was of interest that the greatest power came 
from discordant siblings. Twelve of the 41 siblings were 
discordant for the high risk DAT
1
 alleles (10 repeat), and 
in 10 of these, the siblings carrying the high risk alleles 
had signifi cantly higher scores for hyperactive-impulsive 
symptoms and for inattentive symptoms. The transmission 
disequilibrium test also showed association and linkage of 
the 10 repeat with the combined form of ADHD. Of the 
10 studied, eight were positive for a role of the DAT
1
 gene 
in ADHD. Winsberg and Comings (1999) examined the 
correlation between response to methylphenidate treatment 
and DAT
1
 genotype in a series of 30 African-American 
children with ADHD. Of the responders, only 31% carried 
the 10/10 genotype while 86% of the non-responders 
carried the 10/10 genotype, suggesting that in this 
population 10/10 homozygosity is associated with a poor 
response to stimulant treatment. Although these interesting 
pharmacogenomic fi ndings have been confi rmed by some 
(Kirley et al 2003), they await further replication.
A recent meta-analysis concluded that there is a signifi -
cant association between ADHD and dopamine system genes, 
such as DAT
1
, but even more robust with regard to the DRD
4
 
and DRD
5
 genes (Li et al 2006). Of further interest, Mill et al 
(2006) presented evidence that polymorphisms in the DRD
4
 
and DAT
1
 genes were associated with variation (compro-
mise) in intellectual functioning among children diagnosed 
as having ADHD. The same authors further showed from 
longitudinal evidence that these polymorphisms predicted 
which children with ADHD were at greatest risk for poor 
adult prognosis (also see Heiser et al 2004; Madras et al 
2005; Larsson et al 2006).
Generational association studies 
of dopaminergic genes in RDS probands 
and family members
At this point, it is important to emphasize that polymorphisms 
of the dopamine D
2
 receptor gene are associated with RDS 
and a number of related impulsive, addictive, and compulsive 
behaviors. In an unpublished study with Joel Lubar from 
the University of Tennessee, Knoxville, and Judith Lubar at 
the Southwestern Biofeedback and Neurobehavioral Clinic, 
the authors genotyped 51 subjects from four generations 
derived from two multiply-affected families All subjects 
were genotyped for three of the dopaminergic genes (DRD
2
, 
DAT
1
, and DBH). In this study 80% of all subjects (40 of 
50) carried the DRD
2
 Taq 1A1 allele. When compared with 
“highly screened controls called super controls” (1/30 or 
3.3% of the controls carried the DRD
2
 A1 allele), a highly 
signifi cant association was observed. It is noteworthy that as 
the number of RDS behaviors increased in the subjects, the 
prevalence of the DRD
2
 A1 allele also increased. This work 
allows one to utilize genotyping to access certain personality 
factors such as ADHD and other related RDS behaviors.
The role of polygenes as a diagnostic 
indicator
While there is much evidence for the involvement of the 
dopaminergic system and specifi c genes involved and treat-
ment possibilities, other models including genes related 
to dopamine D
4
, dopamine D
5
, dopa decarboxylase gene, 
norepinephrine, adrenergic
2a
 and 
2c
, COMT, tryptophan 2,3-
dioxygenase, and GABA should also be considered (see a 
review by Comings (2001)).
In terms of polygenic inheritance, Hawi et al (2005) 
observed that several genes are associated with ADHD, 
including DAT
1
, DBH, DRD
4
, DRD
5
 and 5HT1B. Moreover, 
linkage studies using affected sibling pairs and extended 
pedigrees have identified several chromosomal regions 
containing putative ADHD susceptibility genes. Chromosomal 
regions highlighted by replication across studies are 
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accumulating evidence with increasing sample size and 
include chromosomes 5p13, 6q12, 16p13, and 17p11 (Arcos-
Burgos et al 2004; Asherson et al 2005).
Kent et al (2005) found evidence to support the 
hypothesis that the gene BDNF (brain-derived neurotrophic 
factor) located at 11p13 and encoding for a precursor peptide 
(proBDNF), is associated with ADHD. Additionally, Turic 
and others (2005a) found evidence that genes related to 
glutamate function such as SLC1A3 (Solute Carrier Fam-
ily 1, member 3) in a family based study may contribute 
to susceptibility to ADHD. Other genes that have been 
associated with ADHD susceptibility include the calcyon 
gene (DRD11p) (Laurin et al 2005); beta hydroxylase gene 
(Inkster et al 2004) NR4A2 gene (Smith et al 2005) and the 
COMT gene (Turic et al 2005b).
Understanding the genetic meaning of carrying the 
DRD
2
 and DAT
1
 polymorphisms to assist in the diagnosis of 
ADHD is of paramount importance. One must fi rst consider 
the difference between a single-gene-single-cause concept as 
in the situation with Cystic Fibrosis or Huntington’s disease, 
or even Muscular Dystrophy, compared to multiple genes 
involved in complex disorders such as ADHD (Comings 
et al 1996). With regard to psychiatric genetic anomalies 
such as schizophrenia, bipolar disorder, Alzheimer disease, 
RDS, among other related behaviors, dopaminergic allelic 
presence does not necessarily diagnose the disorder. On 
the other hand if an individual carries one or more of these 
associated polymorphisms, the scientifi c evidence supports 
a diagnosis of predisposition and high probability that the 
subject is at greater risk for having the disorder in question 
or may at some time in the future present with typical 
clinical symptoms. Moreover, we do know from the use of 
Bayes theory to predict outcomes, that carriers born with the 
dopamine D
2
 receptor A1 allele have a 74% chance that they 
would have RDS behavior (Blum et al 1990, 1996b).
This predisposition diagnosis is typical in that the same 
parameters and limitations that have been placed on other 
diseases such as so called oncogenes for cancer, as well 
as the gene for diabetes, are the same for RDS. There is a 
tendency in psychiatric genetics to think in terms of the single-
gene–single-disorder model and to lose sight of the fact that 
polygenic inheritance has its own distinct set of rules. There 
are some distinct issues that are relevant to the genetics of 
ADHD. A major point is that polygenic inheritance is far more 
complex than single gene inheritance. The ultimate truth about 
the role of any one gene involved in polygenic inheritance may 
require a summation across many different studies and the 
examination of the additive genes involved in both childhood 
and adult ADHD and their comorbid disorders. Once the 
gene map of ADHD is uncovered, it will provide improved 
diagnosis (prevent over-diagnosis) and treatment (non-drug, 
non-addictive, effi cacious and safe) of these very common 
disorders and demonstrate for all but the most recalcitrant 
critic that these are real biological entities.
Comings (2001) summarized the role of multiple genes 
in ADHD providing a polygenic model for the etiology 
of ADHD including the following salient points modifi ed 
herein:
• Multiple dopaminergic genes and other genes each 
contributing to a small percentage of the total variance.
• The co-morbidity between ADHD and substance abuse 
(common sets of genes affecting the frontal lobes and the 
reward pathways).
• The central role of the frontal lobes and ADHD and 
related disorders.
• The evidence from animals that defects of dopamine 
metabolism in the frontal lobes are important in ADHD.
• The secondary hypersensitivity of dopamine receptors in 
the basal ganglia leading to hyperactivity and tics.
• The close relationship between ADHD and Tourette 
syndrome.
• The role of norepinephrine genes in learning and language 
disorders involving parietal lobe attention centers.
• The role of serotonergic and GABAergic genes in the 
reward cascade.
• The role of enkephalinergic genes as they relate to 
dopamine release.
Treatments for ADHD
The website for the American Academy of Child and 
Adolescent Psychiatry (AACP) states, “The goal of any 
type of ADHD treatment is to reduce symptoms and help 
the child function at a normal level. Treatment may include 
medication, therapy, family support, educational support, or 
a combination of these” (http://www.aacap.org/cs/adhd_a_
guide_for_families/getting_treatment).
Symptoms of ADHD often are treated with drugs, an 
approach that conforms to mainstream medical and regulatory 
guidelines. Common conventional therapies are targeted at 
suppressing symptoms by inhibiting, blocking, or (conversely) 
amplifying production, reception and/or disposal of various 
neurotransmitters (eg, serotonin with selective serotonin 
reuptake inhibitors). These therapies carry some associated 
undesirable risks. When pharmacological agents are admin-
istered to children, reactions often are polarized. Some 
critics object to the prospect of millions of children who are 
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prescribed controlled substances that are potentially addic-
tive and injurious to the brain. Others support the opportunity 
given to people diagnosed with ADHD (including adults) for 
receiving the clinical attention they deserve, including effective 
treatment, despite side effects. Whatever treatment option is 
chosen, in order to provide an effective outcome for individuals 
with ADHD, it is important to recognize the following: First, 
individuals may be born with a predisposition to behavioral 
symptoms associated with ADHD and other RDS disorders. 
Second, these various RDS disorders involve complex interac-
tions of neurotransmitters. Third, ADHD may be the precursor 
for multiple addictions including alcohol, drugs, food, sex, and 
even gambling. And fourth, there is an association between 
a severe form of alcoholism and defects in the D
2
 gene in 
the reward area of the brain and other dopaminergic genes 
(ie, the dopamine transporter gene and the dopamine beta-
hydroxylase gene) (Blum et al 1996a; Pohjalainen et al 1998; 
Bowirrat and Oscar-Berman 2005). While the genetics are 
far more complex than these genes, carriers of dopaminergic 
gene variants, or genetic defi cits including these or other gene 
subsets, can develop behavioral manifestations of RDS.
Pharmacological treatments
Stimulants
Pharmacological treatment with psychostimulants is the most 
widely studied treatment for ADHD. Stimulant treatment 
has been used for childhood behavioral disorders since 
1933. While stimulant treatments are highly effective for 
75%–90% of children with ADHD, at least four separate 
psychostimulant medications consistently reduce the core 
features of ADHD in literally hundreds of randomized 
controlled trials: methylphenidate, dextroamphetamine, 
pemoline, and a mixture of amphetamine salts.
These medications are metabolized, leave the body fairly 
quickly, and work for up to four hours. (Widely prescribed 
drugs, Concerta and Adderall, are believed to last 6–12 hours.) 
These medications have their greatest effects on symptoms of 
hyperactivity, impulsivity, and inattention, and the associated 
features of defi ance, aggression, and oppositionality. They 
also improve classroom performance and behavior, promoting 
increased interaction with teachers, parents and peers.
Many double blind studies over the past 40 years have 
uniformly agreed that stimulants such as methylphenidate, 
dextro-amphetamine, as well as other substances, are very 
effective in the treatment of 70%–80% of children and adults 
with ADHD. One of the myths of ADHD is that ADHD 
children show a paradoxical effect of being calmed by stimulants, 
while “normal” individuals are stimulated by them. However, 
studies have shown that the activity levels are decreased and 
attention levels are increased by stimulants in individuals with 
and without ADHD. The difference is that since the levels of 
hyperactivity and inattention are much higher in ADHD subjects, 
the improvement is relatively much greater, giving the impression 
that they respond, while non-ADHD subjects do not.
It is known that like the effect of serotonin re-uptake 
inhibitors on the serotonin transporters, stimulants inhibit 
both dopamine transporters and norepinephrine transporters. 
Since hyperactivity is related to excessive dopamine activity 
in the basal ganglia, on the surface this would seem to make 
things worse instead of better. However, Figure 2 shows how 
the stimulants work in ADHD. This results in a decrease 
in dopaminergic stimulation in the basal ganglia where the 
density of the D
2
 receptors is the highest. Of particular inter-
est, there are few D
2
 receptors in the prefrontal lobe. Thus, 
dopamine activity in the prefrontal lobes is increased instead 
of decreased. This is consistent with a model of ADHD in 
which there is too little dopamine in the frontal lobes, result-
ing in symptoms of prefrontal lobe defi cits and too much 
dopamine in the basal ganglia, such as motor hyperactivity 
and not infrequently, motor tics. The stimulants correct both 
the prefrontal lobe defi ciency of dopamine and the basal 
ganglion excess of dopamine.
Despite this indication of how uniquely suited stimulant 
medications are to the treatment of ADHD, they can have 
undesirable side effects such as insomnia, decreased appetite, 
stomachaches, headaches, and jitteriness. Some children 
may develop tics. Other side effects include rebound hyper-
activity and psychosis. Pemoline has been associated with 
hepatotoxicity, so monitoring of liver function is necessary. 
Additionally, many still worry that ADHD children are 
receiving a form of “speed”. Studies have shown that in order 
to obtain a “high”, stimulants need to reach the brain very 
quickly. This requires intravenous or nasal administration, or 
the use of doses that exceed therapeutic recommendations. At 
therapeutic oral doses, the stimulants used for treatment of 
ADHD do not cause a euphoric high. Perhaps the best indica-
tor of this is that one of the hardest parts of the treatment for 
ADHD children is to get them to take their medication. This, 
however, is no guarantee that these drugs are never abused. 
It is important that children and adolescents with ADHD not 
have free access to their medications, since it is clear that 
these drugs can be abused when given nasally, or intrave-
nously, or in high doses. Keeping track of the medications 
helps to ensure that they are not sold for illicit use.
In addition to the use of stimulant medications, a second 
class of medications that works primarily on norepinephrine 
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pathways (eg, clonidine, guanifacine, and atomoxetine, 
can also be quite effective (Perwien et al 2006; Spencer 
et al 2001, 2006). Clonidine and guanifacine are especially 
useful in treating individuals with both ADHD and chronic 
tics (Tourette syndrome) since clonidine and guanifa-
cine uniquely treat both ADHD and Tourette syndrome. 
Physicians are often reluctant to treat individuals with both 
ADHD and Tourette syndrome with stimulants, for fear of 
exacerbating the tics. However, consistent with the above 
mechanism of action of stimulants, signifi cant exacerbation 
is unusual, and often the tics are unchanged or improve 
following stimulant treatment (Gadow et al 1992).
As alluded to above, it is often the comorbid disorders 
such as ODD and CD that cause the greatest distress to 
parents of children with ADHD. In our experience, the 
atypical neuroleptics such as risperidone, olanzipine, and 
molindone, can be very effective in the treatment of these 
comorbid conditions.
Other medications
For children with ADHD who do not respond to stimulants 
(10%–30%) or cannot tolerate the side effects, other alterna-
tives may be available. However, other competitive solutions 
also have been tried with mixed results (Friel 2007). The 
anti-depressant bupropion has been found to be superior to 
placebo, although the response is not as strong as stimulants. 
Well-controlled trials have shown tricyclic antidepressants 
to be superior to placebo but less effective than stimulants. 
Normal at rest Normal with nerve impulses
Stimulant at rest Stimulant with nerve impulse
dopamine 
transporter
dopamine 
transporter 
blocked with 
Ritalin or 
Dexedrine
presynaptic 
dopamine D2
receptor
presynaptic 
dopamine D2
receptor 
stimulated
decreased 
dopamine  
release
Figure 2 Diagrammatic representation of the mechanisms of action of stimulants in treating ADHD. Figure 2a (top left) shows the basal unstimulated state with dopamine stored 
in the vesicles and low levels of dopamine in the synapse. Figure 2b (top right) shows the result of stimulation of the dopamine neuron with the vesicles releasing dopamine 
into the synapse and re-uptake of dopamine into the presynaptic neuron by the dopamine transporters. Figure 2c (bottom left) shows that in the presence of stimulants, 
the function of the dopamine transporters is partially blocked and the basal level of dopamine increases in the synapse. This results in the occupation of the presynaptic 
dopamine D2 receptors by dopamine. Now, when the nerve is stimulated (Figure 2d, bottom right), because of the occupation of the presynaptic D2 receptors, the amount of 
dopamine released from the vesicles is decreased. Adapted from Seeman and Madras (1998).
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Reports of sudden death of a few children in the early 1990s 
on the tricyclic compound desipramine led to great caution 
with the use of tricyclics in children.
Clonidine can be an effective mode of treatment of 
ADHD. Since it also treats motor and vocal tics, it is espe-
cially useful in the treatment of Tourette-syndrome children 
who also have ADHD. Neuroleptics have been found to be 
occasionally effective, yet the risk of movement disorders, 
such as tardive dyskinesia, makes their use problematic. 
Lithium, fenfl uramine, or benzodiazepines have not been 
found to be effective treatments for ADHD, nor have sero-
tonin re-uptake inhibitors such as fl uoxetine.
Another drug being tested is lisdexamfetamine 
dimesylate (LDX), a therapeutically inactive prodrug in 
which d-amphetamine is covalently bound to l-lysine, a 
naturally occurring amino acid. Pharmacologically active 
d-amphetamine is released from LDX following oral 
ingestion. A phase 2, randomized, double-blind, placebo- 
and active-controlled crossover study compared the effi cacy 
and safety of LDX (30, 50, or 70 mg) with placebo, with 
mixed amphetamine salts (extended-release 10, 20, or 30 
mg) included as a reference arm of the study, in 52 ADHD 
children aged 6–12 years in an analog classroom setting 
(Biederman et al 2007a). The primary effi cacy measure was 
the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) 
Rating Scale. Secondary effi cacy measures included the 
Permanent Product Measure of Performance (PERMP) 
Derived Measures, and the Clinical Global Impression (CGI) 
Scale. Results showed that LDX treatment signifi cantly 
improved scores on SKAMP-deportment, SKAMP-attention, 
PERMP-attempted, PERMP-correct, and CGI-improvement 
from baseline. Adverse events were similar for both active 
treatments. In a laboratory classroom environment, LDX 
signifi cantly improved ADHD symptoms versus placebo in 
school-age children with ADHD.
Overprescription of stimulants
Concerns have been raised that children, particularly active 
boys, are being overdiagnosed with ADHD and thus are 
receiving psychostimulants unnecessarily. While recent 
reports suggest that overprescription and overdiagnosis are 
unfounded, a more important issue is that fewer children 
(2%–3% of school-aged children) are being treated for 
ADHD than suffer from it (Farone 2003). Treatment rates 
are lower for selected groups such as girls, minorities, and 
children receiving care through public service systems. 
However, there have been major increases in the number 
of stimulant prescriptions since 1989, and methylphenidate 
is being manufactured at 2.5 times the rate of a decade ago 
(Comings et al 2005). Nonetheless, some of the increase in 
use may refl ect inappropriate diagnosis and treatment. In 
one study, the rate of stimulant use was twice the rate of 
parent-reported ADHD, based on standardized psychiatric 
interview (Comings et al 2005). Moreover, in 2005, 4.4% of 
children (ages 0–19) and 0.8% of adults (ages 20 and older) 
used ADHD medications. During the period between 2000 
and 2005, treatment prevalence increased rapidly (11.8% per 
year; Castle et al 2007). In addition, global use of ADHD 
medications rose threefold from 1993 to 2003, whereas global 
spending (US$2.4 billion in 2003) rose 9-fold, adjusting for 
infl ation (Scheffl er et al 2007).
While a number of stimulant drugs are utilized to treat 
ADHD symptoms, a promising alternative approach involves 
a natural polypharmacy directed at correction and control 
of neurochemistry and dopamine D
2
 receptor proliferation, 
while minimizing side effects (Blum et al 2006a). It also 
involves a noninvasive DNA based diagnostic test for the 
determination of predisposing sets of polymorphic genes 
and their interaction (known as epistasis). However, this 
treatment approach also can be accomplished in combination 
with known FDA-approved stimulants.
The polypharmacy and multigenetic 
approach
The polygenic inheritance of ADHD and its comorbid 
disorders makes the need for more than one medication 
(polypharmacy) easy to understand as an optimal treatment 
of complex cases. Thus, the involvement of variant 
dopamine genes resulting in ADHD and tics may require 
dopaminergic agonists (methylphenidate or dexedrine) 
or antagonists (haloperidol, pimozide, risperidone, etc.). 
The involvement of variant norepinephrine or epinephrine 
genes resulting in ADHD and behavioral dysregulation, may 
require a
2
-adrenergic agonists (eg, clonidine, guanifacine, 
venlafaxine, and atomoxetine). The involvement of variant 
serotonergic genes resulting in depression and anxiety 
disorders may require selective serotonin re-uptake inhibitors 
(eg, fl uoxetine, sertraline, paroxetine, and fl uvoxamine). The 
involvement of other variant genes resulting in ODD, CD, and 
other behaviors, may require medications such as valproic 
acid, molindone, and risperidone (Biederman et al 2007b).
Parents often raise legitimate concerns when their children 
are placed on any medication, let alone two or more. Explaining 
ADHD in terms of a complex set of different genes affecting 
different neurotransmitters often helps to moderate these 
concerns. To this effect, the utilization of certain specifi c 
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ingredients, which modify the brain reward cascade by targeting 
serotonergic, opioidergic, GABAergic, catecholaminergic, 
and acetylcholinergic pathways, can alter behaviors known 
to be associated with ADHD. Such a polypharmacy approach 
may include the utilization of a nutraceutical (nutrigenomic) 
approach targeted at enhancing slow dopamine release in the 
nucleus accumbens. One available nutraceutical combines 
the following: select amino acids (5-hydroxytyptophan, dl-
Phenylalanine, l-tyrosine, l-glutamine); herbals (Rhodiola 
rosea, ferulic acid, ginkgo-biloba, ginseng, gotu kola, huperzine 
A); trace metals (chromium and zinc); macro minerals (calcium, 
magnesium, manganese); vitamins (ascorbic acid, d-alpha 
tocopheryl, niacin, pyridoxal-phosphate, B12); and co-factors 
(biotin, folic acid, dimethylethanoiamine).
In an early study of healthy volunteers, a combination of 
amino acids and herbals showed positive results (Defrance 
et al 1977). The researchers observed a signifi cant amplitude 
enhancement of the P300 component of the cognitive event-
related brain potentials, as well as improvement in cognitive 
processing speeds, after the subjects were given the amino 
acid formula. These improvements in normal volunteers are 
consistent with the observed facilitation of recovery of indi-
viduals with RDS, including substance abuse and ADHD, as 
well as with dopaminergic involvement in short term memory 
(Kimberg et al 1997).
Combination therapy: a long-term 
approach
The short-term safety and tolerability of psychostimulants 
has been reasonably well studied, and the risks associated 
with these compounds in the short term are generally accept-
able. However, the amount of long-term effectiveness and 
safety data related to psychostimulant therapy is relatively 
small. Data that do exist suggest that long-term treatment 
with psychostimulants in appropriately diagnosed patients 
may be associated with salutary effects as well as relatively 
modest risks. (Kociancic et al 2004). ADHD has an early 
onset and requires an extended course of treatment. Research 
is needed to examine the long-term safety of treatment and 
to investigate whether other forms of treatment could be 
combined with psychostimulants to lower their doses as well 
as to reduce other problem behaviors found with ADHD. 
One important treatment goal is to develop a side-effect free 
natural product to augment psychostimulants with the ulti-
mate goal of reducing the need for psychostimulants. Core to 
this therapeutic strategy would be to develop a product with 
mechanisms of action that would both increase the release 
of dopamine, and induce long term D
2
 receptor proliferation. 
Such a novel combination therapy would mimic stimulants 
like methylphenidate, and thus an additive and/or synergistic 
action should be expected.
In fact, combined therapies might be used to improve 
overall functioning by targeting symptoms of disorders that 
often accompany ADHD, such as CD, SUD, and learning 
disabilities. Moreover, because stimulants also can be abused, 
and because children with ADHD are at increased risk for 
substance-seeking behavior, concerns have been raised 
about the potential for abuse of stimulants by children tak-
ing medication or migrating to other drugs of abuse. In this 
regard, critics argue that many children who do not have 
true ADHD are medicated as a way to control non-ADHD 
disruptive behaviors. However, ironically, organizations 
like CHADD recommend the use of stimulants for school-
aged children, comparing the pills to eyeglasses, braces, and 
allergy medications (CHADD 2007).
In this regard, the use of methylphenidate and amphet-
amine, which are the mainstay for the treatment of ADHD, 
has raised concerns because of their reinforcing effects. That 
is, the chronic use of these medicines during childhood or 
adolescence might induce changes in the brain that could 
facilitate drug abuse in adulthood. This concern was recently 
addressed by Thanos and colleagues (Thanos et al 2007). 
They measured the effects of chronic treatment (8 months) 
with oral methylphenidate (1 or 2 mg/kg), which was initi-
ated in periadolescent rats (postnatal day 30). Following this 
treatment, the rats were tested on cocaine self-administration. 
In addition, at 2 and 8 months of treatment, the investiga-
tors measured dopamine D
2
 receptor (D
2
R) availability in 
the striatum using [(11)C]raclopride microPET (muPET) 
imaging. Animals treated for 8 months with 2 mg/kg of meth-
ylphenidate showed signifi cantly reduced rates of cocaine 
self-administration at adulthood compared to vehicle-treated 
rats. D
2
R availability in the striatum was signifi cantly lower 
in rats after 2 months of treatment with methylphenidate 
(1 and 2 mg/kg) but signifi cantly higher after 8 months of 
methylphenidate treatment than in the vehicle-treated rats. 
In vehicle-treated rats, D
2
R availability decreased with age, 
whereas it increased in rats treated with methylphenidate. 
Because low D
2
R levels in the striatum are associated with 
a propensity for self-administration of drugs both in labora-
tory animals and in humans, this effect could underlie the 
lower rates of cocaine self-administration observed in the 
rats given 8 months of treatment with methylphenidate. 
Eight-month treatment with oral methylphenidate begin-
ning in adolescence decreased cocaine self-administration 
(1 mg/kg) during adulthood which could refl ect the increases 
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in D
2
R availability observed at this life stage since D
2
R 
increases are associated with reduced propensity for cocaine 
self-administration. In contrast, 2-month treatment with 
methylphenidate started also at adolescence decreased D
2
R 
availability, which could raise concern that at this life stage, 
short treatments could possibly increase vulnerability to 
drug abuse during adulthood. These fi ndings indicate that 
methylphenidate effects on D
2
R expression in the striatum 
are sensitive not only to length of treatment but also to 
the developmental stage at which treatment is given. The 
authors suggested that future studies evaluating the effects 
of different lengths of treatment on drug self-administration 
are required to assess optimal duration of treatment regimes 
to minimize adverse effects on the propensity for drug self-
administration in humans.
Little is known about the risks and characteristics of 
ADHD patients who misuse or divert their stimulant medica-
tions. As part of a 10-year longitudinal study of youths with 
ADHD, Wilens et al (2006) evaluated medication diversion 
or misuse in a young ADHD population. The investigators 
used structured psychiatric interviews for diagnosis, and a 
self-report questionnaire regarding medication use in medi-
cated subjects with ADHD compared with controls without 
ADHD receiving psychotropic medications for non-ADHD 
treatment. Of 98 subjects receiving psychotropic medications 
(mean age of 20.8 ± 5 years), 55 (56%) were ADHD subjects 
and 43 (44%) were controls receiving medications for other 
purposes. The authors found that 11% of the ADHD group 
reported selling their medications compared with no subjects 
in the control group. An additional 22% of the ADHD group 
reported misusing their medications compared with 5% of the 
control subjects, and that those with CD or SUD accounted 
for the misuse and diversion. A minority of subjects reported 
escalating their doses and concomitant use with alcohol 
and drugs. Interestingly, the data indicated that the majority 
of ADHD individuals, particularly those without CD or SUD, 
used their medications appropriately. The authors' fi ndings 
also highlighted the need to monitor medication use in 
ADHD individuals with CD or SUD and to carefully select 
agents with a low likelihood of diversion or misuse in this 
group. Based on this report, therefore, it may be helpful for 
individuals to be tested for candidate genes to determine a 
predisposition of substance seeking-behavior.
In terms of methamphetamine utilization, there are con-
cerns related to its genotoxic effects. A recent study was 
conducted to investigate the index of cerebral and peripheral 
DNA damage in young and adult rats after acute and chronic 
methylphenidate exposure. The researchers used single cell 
gel electrophoresis (Comet assay) to measure early DNA 
damage in hippocampus, striatum, and total blood, as well 
as a micronucleus test in total blood samples. Their results 
showed that methylphenidate increased the peripheral 
index of early DNA damage in young and adult rats, which 
was more pronounced with chronic treatment and in the 
striatum compared to the hippocampus. Neither acute nor 
chronic methylphenidate treatment increased micronucleus 
frequency in young or in adult rats. Peripheral DNA damage 
was positively correlated with striatal DNA damage. These 
results suggest that methylphenidate may induce central and 
peripheral early DNA damage, but this early damage may 
be repaired (Andreazza et al 2007).
Alternative treatments
Because of the concern about the use of medications, many 
parents seek alternative methods of treatment of ADHD. 
Most clinicians agree that a combination of medication and 
behavioral modifi cation is the most effective approach to the 
treatment of ADHD, even though the medications appear 
to contribute greater benefi ts. Children with ADHD may 
also respond well to adjustments in their education setting, 
eg, taking advantage of an individualized educational plan. 
The following are some additional alternatives that are most 
often used.
EEG biofeedback
Electroencephalographic (EEG) biofeedback usually utilizes 
the feedback from a game played on a TV screen to attempt 
to train the brain to alter the levels of alpha, beta and delta 
waves. This tactic has the advantage that no drugs are used 
and appears to be effective in some cases. The disadvantage 
is that it can be expensive. Satisfactory double blind testing 
and evaluation of its effectiveness has been very diffi cult, 
and the effects may not be long lasting.
Herbal remedies
Numerous herbal remedies have been used by ADHD 
patients. Sometimes they seem to be effective, sometimes not, 
or their effectiveness may be short-lived. Many parents turn 
to them because they are perceived as “natural”. However, to 
be effective they must contain an active ingredient for which 
the identity is usually not known. In addition, a wide range 
of other ingredients may be present that are not necessary or 
may cause unknown, or worse yet, undesirable side effects. 
As physicians and pharmacologists, we suggest that using 
pure medications with known doses, known mechanisms of 
action and known side effects is always preferable.
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Nutraceuticals
In contrast to herbal remedies, the composition of other 
nutraceuticals is more precisely known. They usually con-
sist of amino acids, vitamins, minerals, and other known 
compounds. Because they are closer to food substances 
than drugs, they do not have the same rigorous restrictions 
by the Federal Drug Administration that drugs do and can 
be purchased over the counter. Because a number of amino 
acids have direct or indirect effects on the levels of specifi c 
neurotransmitters, they have the potential of helping to con-
trol some of the symptoms of ADHD. Nutraceuticals have the 
advantage that double-blind studies (Blum et al 1988) can be 
easily carried out. It is not unlikely that some combinations 
of the above compounds, carefully tested in double-blind 
studies, may play a supporting role in controlling some of the 
symptoms of ADHD (Blum and Trachtenberg 1988; Blum 
et al 2000, 2006b; Blum and Payne 1991; Chen et al 2004).
Diets and vitamin supplements
Hardy et al (2003) compared attentional abilities of two 
groups of children with ADHD, one group after treatment 
with Ritalin, and the other after treatment with dietary supple-
ments (a mix of vitamins, minerals, phytonutrients, amino 
acids, essential fatty acids, phospholipids, and probiotics). 
Both groups showed signifi cant improvement. These fi ndings 
support the effectiveness of food supplement treatment in 
improving attention and self-control in children with ADHD 
and suggest food supplement treatment of ADHD may be of 
equal effi cacy to Ritalin® treatment.
Dopaminergic and serotonergic releaser 
combination therapy
Another treatment for substance-seeking behaviors consists of 
agonist therapy (not antagonist therapy). This strategy involves 
administration of stimulant-like medications (eg, monoamine 
releasers) to alleviate withdrawal symptoms and prevent 
relapse. A major limitation of this approach is that many can-
didate medicines possess signifi cant abuse potential because of 
activation of mesolimbic dopamine neurons in central nervous 
system reward circuits. Previous data suggest that serotonin 
neurons can provide regulatory infl uence over mesolimbic 
dopamine neurons. Thus, it might be predicted that the balance 
between dopamine and serotonin transmission is important to 
consider when developing medications with reduced stimulant 
side effects. In this article, we have discussed several issues 
related to the putative mechanisms related to ADHD behaviors. 
In other recent articles the authors have discussed the potential 
development of dual dopamine/serotonin releasers for the 
treatment of substance use disorders (Rothman et al 2007). In 
this regard, there is evidence supporting the existence of a dual 
defi cit in dopamine and serotonin function during withdrawal 
from chronic cocaine or alcohol abuse (Rothman et al 2007). 
Rothman and associates further summarize studies that have 
tested the hypothesis that serotonin neurons can dampen the 
effects mediated by mesolimbic dopamine. For example, it has 
been shown that pharmacological manipulations that increase 
extracellular serotonin attenuate stimulant effects produced 
by dopamine release, such as locomotor stimulation and self-
administration behavior. Finally, they discuss their recently 
published data about PAL-287 (naphthylisopropylamine), 
a novel non-amphetamine dopamine/serotonin-releasing 
agent that suppresses cocaine self-administration but lacks 
positive reinforcing properties (Hiebel et al 2007). Using 
this concept we have developed the Synaptamine Complex 
(SG8839)™ and have recently published on its effects (Chen 
et al 2004). Table 3 provides details about the ingredients of 
the synaptamine complex, as well as proposed brain targets 
and behavioral changes.
At the recent XV World Congress of Psychiatric genetics 
held in New York City, a number of new gene loci presented 
at the congress included: Nos1 exon 1f-VNTF; NTF3; 
CNTFR; NTRK2; rs2242447 (noradrenergic transporter 
gene); HTR1B; beta-tubulin 111; MAP2; ADRA2A; and 
linkage to chromosome 3, 9, and 16 among others.
Summary
ADHD is a complex disorder, usually appearing fi rst in 
childhood, and having multiple causes including genetics 
as impacted by one’s environment. In order to dispel myths 
about ADHD, it will require examination of the additive 
effects of multiple genes. Further, and because polygenic 
inheritance is far more complex than single gene inheri-
tance, an ultimate understanding of the role of any one gene 
involved in polygenic inheritance will require a summation 
across many different studies. While the use of psychostimu-
lants has resulted in attenuation of behavioral symptoms in a 
high percentage of ADHD children, parents have been con-
cerned about potential side effects. In this regard, the extant 
evidence tends to support the novel concept of an adjunctive 
polypharmacy approach for the prevention and treatment of 
ADHD rather than single neurochemical and/or neurogenetic 
targets (eg, D
1
-D
5
, DAT
1
, DBH, COMT, 5HT1B, NR4A2, 
SLC1A3, BDNF, as well as loci at 4q13.2, 5q33.3, 11q22 
and 17p11 [see above]).
Hopefully, because of advances in molecular 
pharmacology, nutrition, and molecular genetics, the legacy 
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of RDS and subtype ADHD behavior will be reduced. In order 
to advance these goals, we recommend diagnosis of ADHD 
using the specifi c DNA polymorphic analysis coupled with 
electrophysiological and computerized testing, especially in 
young children. In this regard, (Larsson et al 2006) suggested 
that the fi nding of persistent cross-subtype (ie, combined) 
and persistent subtype-specifi c genetic infl uences (ie, pri-
marily hyperactive-impulsive and inattentive disorders) are 
in line with a genetic basis for the DSM-IV classifi cation of 
ADHD subtypes (Table 1). Finally, considerable evidence 
suggests that, rather than a single pharmaceutical treatment 
approach, DNA-based personalized nutraceutical therapies 
should be considered.
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